Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSTM2 | P28161 | 1/20 | 0.61 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.57 |
| ▸ | S1PR1 | P21453 | 3/20 | 0.46 |
| ▸ | S1PR3 | Q99500 | 3/20 | 0.46 |
| ▸ | S1PR4 | O95977 | 2/20 | 0.46 |
| ▸ | S1PR5 | Q9H228 | 2/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | USP2 | O75604 | 1/20 | 0.45 |
| ▸ | HTT | P42858 | 1/20 | 0.45 |
| ▸ | RECQL | P46063 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | SUCNR1 | Q9BXA5 | 1/20 | 0.44 |
| ▸ | HTR3A | P46098 | 1/20 | 0.43 |
| ▸ | MYC | P01106 | 1/20 | 0.43 |
| ▸ | MIF | P14174 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13795300 | 1.00 | GSTM2 (0.61) | GSTM2HRH3S1PR1S1PR3S1PR4 | |
| SCHEMBL12900559 | 0.86 | GSTM2 (0.51) | GSTM2HRH3MEN1USP2HTT | |
| SCHEMBL5191249 | 0.84 | GSTM2 (0.55) | GSTM2HRH3S1PR1S1PR3S1PR4 | |
| SCHEMBL20101720 | 0.83 | GSTM2 (0.49) | GSTM2HRH3MEN1USP2HTT | |
| SCHEMBL28933688 | 0.81 | KAT2B (0.49) | MEN1KMT2A | |
| SCHEMBL31320442 | 0.81 | GSTM2 (0.76) | GSTM2HRH3S1PR1S1PR3S1PR4 | |
| SCHEMBL30892505 | 0.81 | GSTM2 (0.76) | GSTM2HRH3S1PR1S1PR3S1PR4 | |
| SCHEMBL15515612 | 0.81 | GSTM2 (0.76) | GSTM2HRH3S1PR1S1PR3S1PR4 | |
| SCHEMBL459120 | 0.81 | GSTM2 (0.76) | GSTM2HRH3S1PR1S1PR3S1PR4 | |
| SCHEMBL285019 | 0.81 | GSTM2 (0.76) | GSTM2HRH3S1PR1S1PR3S1PR4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 124 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090054532-A1 | Modulators of Retinol-Retinol Binding Protein (RBP)-Transthyretin (TTR) Complex Formation | SIRION THERAPEUTICS, INC. (US) | 2009-02-26 | — | — | US | claimed |
| EP-1807103-A2 | MODULATORS OF RETINOL-RETINOL BINDING PROTEIN (RBP)-TRANSTHYRETIN (TTR) COMPLEX FORMATION | Sirion Therapeutics, Inc. (US) | 2007-07-18 | — | — | EP | claimed |
| WO-2006052860-A2 | MODULATORS OF RETINOL-RETINOL BINDING PROTEIN (RBP)-TRANSTHYRETIN (TTR) COMPLEX FORMATION | SIRION THERAPEUTICS, INC. (US) | 2006-05-18 | — | — | WO | claimed |
| US-20060094063-A1 | Modulators of retinol-retinol binding protein (RBP)-transthyretin (TTR) complex formation | SYTERA, INC. (US) | 2006-05-04 | — | — | US | claimed |
| US-20260092919-A1 | REAGENT FOR MEASURING TYROSINE KINASE ACTIVITY, AND USE THEREOF | HILO CO. LTD. (JP) | 2026-04-02 | — | — | US | disclosed |
| EP-4589011-A1 | REAGENT FOR MEASURING TYROSINE KINASE ACTIVITY, AND USE THEREOF | Hilo Co., Ltd. (JP) | 2025-07-23 | — | — | EP | disclosed |
| US-12195753-B2 | Nucleic acid and other compositions and methods for the modulation of cell membranes | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2025-01-14 | — | — | US | disclosed |
| US-20240316052-A1 | MITOCHONDRIAL SUPERCOMPLEX FORMATION PROMOTER, COMPOSITION FOR MAINTAINING OR IMPROVING MUSCULAR STRENGTH, THERAPEUTIC OR PREVENTATIVE PHARMACEUTICAL COMPOSITION FOR DISEASES WHICH DECREASE MITOCHONDRIAL FUNCTION OR MUSCULAR FUNCTION, AND SCREENING METHOD FOR SUBSTANCES WHICH CONTRIBUTE TO FORMATION OF MITOCHONDRIAL SUPERCOMPLEX | TOKYO METROPOLITAN GERIATRIC HOSPITAL AND INSTITUTE OF GERONTOLOGY (JP) | 2024-09-26 | — | — | US | disclosed |
| WO-2024058178-A1 | REAGENT FOR MEASURING TYROSINE KINASE ACTIVITY, AND USE THEREOF | ＨＩＬＯ株式会社 | 2024-03-21 | — | — | WO | disclosed |
| EP-3496713-B1 | NAPHTHYRIDINE AZAQUINOLONE TO TREAT DISEASES ASSOCIATED WITH DNA REPEAT INSTABILITY | HOSPITAL FOR SICK CHILDREN (CA) | 2024-03-13 | — | — | EP | disclosed |
| US-11672786-B2 | Methods of treating diseases associated with repeat instability | THE HOSPITAL FOR SICK CHILDREN | 2023-06-13 | — | — | US | disclosed |
| US-20230109020-A1 | Nucleic Acid and Other Compositions and Methods for the Modulation of Cell Membranes | CAMBRIDGE ENTERPRISE LIMITED (GB) | 2023-04-06 | — | — | US | disclosed |
| US-20040014071-A1 | Methods for the detection, analysis and isolation of nascent proteins | AMBERGEN, INC. | 2004-01-22 | — | — | US | disclosed |
| US-20030190643-A1 | Sequencing by mass spectrometry | THE TRUSTEES OF BOSTON UNIVERSITY | 2003-10-09 | — | — | US | disclosed |
| US-20030092031-A1 | Methods for the detection, analysis and isolation of nascent proteins | AMBERGEN, INC. | 2003-05-15 | — | — | US | disclosed |
| US-20020132248-A1 | N-terminal and C-terminal markers in nascent proteins | AMBERGEN, INC. | 2002-09-19 | — | — | US | disclosed |
| EP-1210449-A1 | METHODS FOR THE DETECTION, ANALYSIS AND ISOLATION OF NASCENT PROTEINS | Ambergen, Inc. (US) | 2002-06-05 | — | — | EP | disclosed |
| US-6306628-B1 | PROVIDING TRNA MOLECULE CHARGED WITH AMINO ACID AND FLUOROPHORE MARKER, REACTING TRNA MOLECULE WITH MARKER TO CREATE TRNA/MARKER CONJUGATE WHEREIN AMINO ACID OF TRNA OF TRNA/MARKER CONJUGATE IS COVALENTLY BONDED TO MARKER | AMBERGEN, INCORPORATED | 2001-10-23 | — | — | US | disclosed |
| US-6303337-B1 | ADDING MISAMINOACYLATED INITIATOR TRNA THAT RECOGNIZES ONLY THE FIRST AUG CODON TO TRANSLATION SYSTEM; GENE EXPRESSION, EVALUATION; GENETIC ENGINEERING | AMBER GEN. INC. | 2001-10-16 | — | — | US | disclosed |
| WO-2001014578-A1 | METHODS FOR THE DETECTION, ANALYSIS AND ISOLATION OF NASCENT PROTEINS | AMBERGEN, INC. (US) | 2001-03-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12195753-B2 | Nucleic acid and other compositions and methods for the modulation of cell membranes | ABHD16A, PHOSPHO1, CLPTM1L | GSTM2 3872/4885HRH3 4563/4885S1PR1 1604/4885 |
| US-20090054532-A1 | Modulators of Retinol-Retinol Binding Protein (RBP)-Transthyretin (TTR) Complex Formation | RBP1, TTR, RBP4 | GSTM2 3042/4885HRH3 4219/4885S1PR1 2723/4885 |
| US-20230109020-A1 | Nucleic Acid and Other Compositions and Methods for the Modulation of Cell Membranes | ABHD16A, PHOSPHO1, CLPTM1L | GSTM2 3872/4885HRH3 4563/4885S1PR1 1604/4885 |
| US-20040014071-A1 | Methods for the detection, analysis and isolation of nascent proteins | EIF4A1, NOP2, EIF4A3 | GSTM2 2118/4885HRH3 4678/4885S1PR1 4402/4885 |
| US-20240316052-A1 | MITOCHONDRIAL SUPERCOMPLEX FORMATION PROMOTER, COMPOSITION FOR MAINTAINING OR IMPROVING MUSCULAR STRENGTH, THERAPEUTIC OR PREVENTATIVE PHARMACEUTICAL COMPOSITION FOR DISEASES WHICH DECREASE MITOCHONDRIAL FUNCTION OR MUSCULAR FUNCTION, AND SCREENING METHOD FOR SUBSTANCES WHICH CONTRIBUTE TO FORMATION OF MITOCHONDRIAL SUPERCOMPLEX | TFAM, MAVS, CKMT1A; CKMT1B | GSTM2 946/4885HRH3 4567/4885S1PR1 3262/4885 |
| US-20260092919-A1 | REAGENT FOR MEASURING TYROSINE KINASE ACTIVITY, AND USE THEREOF | CRKL, EGFR, FRK | GSTM2 3262/4885HRH3 1652/4885S1PR1 1499/4885 |
| US-20060094063-A1 | Modulators of retinol-retinol binding protein (RBP)-transthyretin (TTR) complex formation | RBP1, TTR, RBP4 | GSTM2 3042/4885HRH3 4219/4885S1PR1 2723/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.